Milprosa Patent Expiration

Milprosa is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 21, 2030. Details of Milprosa's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580293 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Jan, 2030

(5 years from now)

Active
US10548904 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Feb, 2029

(4 years from now)

Active
US10537584 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Feb, 2029

(4 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Milprosa's patents.

Given below is the list of recent legal activities going on the following patents of Milprosa.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 25 Jul, 2023 US10548904
Payment of Maintenance Fee, 4th Year, Large Entity 11 Jul, 2023 US10537584
Payment of Maintenance Fee, 8th Year, Large Entity 04 May, 2021 US8580293
Patent Issue Date Used in PTA Calculation 04 Feb, 2020 US10548904
Recordation of Patent Grant Mailed 04 Feb, 2020 US10548904
Patent Issue Date Used in PTA Calculation 21 Jan, 2020 US10537584
Recordation of Patent Grant Mailed 21 Jan, 2020 US10537584
Email Notification 16 Jan, 2020 US10548904
Issue Notification Mailed 15 Jan, 2020 US10548904
Email Notification 10 Jan, 2020 US10548904


FDA has granted several exclusivities to Milprosa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Milprosa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Milprosa.

Exclusivity Information

Milprosa holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Milprosa's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 29, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Milprosa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Milprosa's family patents as well as insights into ongoing legal events on those patents.

Milprosa's Family Patents

Milprosa has patent protection in a total of 25 countries. It's US patent count contributes only to 15.7% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Milprosa.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Milprosa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 21, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Milprosa Generics:

Progesterone is the generic name for the brand Milprosa. 11 different companies have already filed for the generic of Milprosa, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Milprosa's generic

Alternative Brands for Milprosa

Milprosa which is used for supporting embryo implantation and early pregnancy in infertile women undergoing ART treatment., has several other brand drugs using the same active ingredient (Progesterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Allergan
Crinone
Covis
Makena (autoinjector)
Ferring
Endometrin
Mayne Pharma
Bijuva
Pfizer
Depo-subq Provera 104
Wyeth Pharms
Premphase 14/14
Prempro


Apart from brand drugs containing the same ingredient, some generics have also been filed for Progesterone, Milprosa's active ingredient. Check the complete list of approved generic manufacturers for Milprosa





About Milprosa

Milprosa is a drug owned by Ferring Pharmaceuticals Inc. It is used for supporting embryo implantation and early pregnancy in infertile women undergoing ART treatment. Milprosa uses Progesterone as an active ingredient. Milprosa was launched by Ferring Pharms Inc in 2020.

Approval Date:

Milprosa was approved by FDA for market use on 29 April, 2020.

Active Ingredient:

Milprosa uses Progesterone as the active ingredient. Check out other Drugs and Companies using Progesterone ingredient

Treatment:

Milprosa is used for supporting embryo implantation and early pregnancy in infertile women undergoing ART treatment.

Dosage:

Milprosa is available in system form for vaginal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1.78GM SYSTEM Discontinued VAGINAL